Search Results for "valsartan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for valsartan. Results 1 to 10 of 11 total matches.
In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication ...
The oral fixed-dose combination of the neprilysin
inhibitor sacubitril and the angiotensin receptor
blocker (ARB) valsartan (Entresto – Novartis) was
approved in 2015 to reduce the risk of cardiovascular
death and hospitalization for heart failure in adults with
chronic heart failure (NYHA Class II-IV) and reduced
ejection fraction (HFrEF; LVEF...
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 14, 2021 (Issue 1626)
of the neprilysin
inhibitor sacubitril and the ARB valsartan (Entresto) is
FDA-approved to reduce the risk ...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
that all patients with HFrEF take an angiotensin receptor-neprilysin inhibitor (ARNI; sacubitril/valsartan ...
View the Comparison Table: Some Drugs for HFrEF
Empagliflozin (Jardiance) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
. At baseline, about 20% of patients were
taking sacubitril/valsartan (Entresto), which is now
recommended ...
In a randomized, placebo-controlled trial, the
sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly)
reduced the composite risk of cardiovascular death
or hospitalization for worsening heart failure (HF)
in patients with heart failure with reduced ejection
fraction (HFrEF), whether or not they had type 2
diabetes. To date, empagliflozin has not been
approved by the FDA for such use. The SGLT2 inhibitor
dapagliflozin (Farxiga) was approved by the FDA for
this indication earlier this year.
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
take an angiotensin receptor-neprilysin
inhibitor (ARNI; sacubitril/valsartan ...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension...
Dapagliflozin (Farxiga) - A New Indication for Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
, only ~11% of patients in each group
were taking sacubitril/valsartan (Entresto), which is now ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga), which was
initially approved by the FDA for treatment of
type 2 diabetes and then to reduce the risk of hospitalization for HF in adults who have type 2 diabetes and established cardiovascular disease
(CVD) or multiple cardiovascular risk factors, has
now been approved for a third indication: to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in patients with heart failure
with reduced ejection fraction (with or without
type 2 diabetes). It is the first SGLT2 inhibitor to...
Empagliflozin (Jardiance) for Heart Failure with Reduced Ejection Fraction
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
%
of the patients had type 2 diabetes and about 20%
were taking sacubitril/valsartan (Entresto), which is
now ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim)
has been approved by the FDA for a third indication: to
reduce the risk of hospitalization for heart failure (HF)
and cardiovascular death in patients with heart failure
with reduced ejection fraction (HFrEF), with or without
type 2 diabetes. The SGLT2 inhibitor dapagliflozin
(Farxiga) was approved for the same indication in
2020. Empagliflozin has been granted breakthrough
therapy designation for treatment of patients with
heart failure with preserved ejection fraction...
Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
%
of the patients had type 2 diabetes and about 20%
were taking sacubitril/valsartan (Entresto), which is
now ...
The FDA has approved an expansion of the
peripheral artery disease (PAD) indication for the
oral direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) to include patients who have recently
undergone a lower extremity revascularization
procedure for symptomatic PAD (see Table 1).
Rivaroxaban is the first direct oral anticoagulant
(DOAC) to be approved for use in patients with PAD.
Apoaequorin (Prevagen) to Improve Memory
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
.
Accessed October 14, 2021. Xarelto valsartan statins sacubitril rivaroxaban Plavix peripheral artery ...
A synthetic form of the protein apoaequorin is the
active ingredient in the over-the-counter dietary
supplement Prevagen (Quincy Bioscience), which
is heavily marketed to improve memory.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
tabs 40-80 mg once/day 26.00
140.30
Valsartan – generic
Diovan (Novartis)
40, 80, 160, 320 mg tabs ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction